Glaukos Corporation (GKOS) Stock Analysis & Investment Frameworks

Glaukos Corporation (GKOS) stock analysis on Invetso. Review Glaukos Corporation’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Glaukos Corporation Company Overview

Glaukos Corporation Key Financial Metrics

About Glaukos Corporation

Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.

Glaukos Corporation Investment Frameworks

Invetso analyzes Glaukos Corporation (GKOS) across the following frameworks:

Explore More GKOS Research